Prognostic value of IL-34 in colorectal cancer patients.


Journal

Immunological medicine
ISSN: 2578-5826
Titre abrégé: Immunol Med
Pays: England
ID NLM: 101736847

Informations de publication

Date de publication:
Dec 2019
Historique:
pubmed: 26 11 2019
medline: 4 8 2020
entrez: 26 11 2019
Statut: ppublish

Résumé

The mortality of colorectal cancer is expected to increase in some countries including the United States, which necessitates the identification of new molecules that help in prognosis assessment and survival improvement. In this brief report, we evaluated the potential of interleukin-34 (IL-34) as a prognostic factor in colorectal cancer. IL-34 was reported for the first time in 2008 as a novel cytokine that controls the biology of the myeloid cell lineage. Accumulating evidence suggests important roles for IL-34 in modifying the tumor microenvironment and enhancing therapeutic resistance of cancer. In this study, we found that IL-34 expression was detectable in various colorectal cancer cell lines in addition to primary cancer tissues from a cohort of Japanese colorectal cancer patients, ranging from high to absent. A Kaplan-Meier analysis showed that high expression of IL-34 correlated with poor survival of colorectal cancer patients. Importantly, in both univariate and multivariate analysis, high IL-34 expression correlated with unfavorable prognosis. A similar relationship between IL-34 expression and the poorer prognosis was also observed in a cohort of colorectal cancer patients registered at The Cancer Genome Atlas. Together, these findings indicate a potential role for IL-34 as a prognostic factor in colorectal cancer.

Identifiants

pubmed: 31762401
doi: 10.1080/25785826.2019.1691429
doi:

Substances chimiques

Biomarkers, Tumor 0
IL34 protein, human 0
Interleukins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

169-175

Auteurs

Takuto Kobayashi (T)

Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

Muhammad Baghdadi (M)

Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

Nanumi Han (N)

Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

Tomoki Murata (T)

Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

Naoki Hama (N)

Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

Ryo Otsuka (R)

Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

Haruka Wada (H)

Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

Manabu Shiozawa (M)

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.

Tomoyuki Yokose (T)

Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan.

Yohei Miyagi (Y)

Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan.

Atsushi Takano (A)

Department of Medical Oncology and Cancer Center, Shiga University of Medical Science, Otsu, Japan.
Center for Advanced Medicine against Cancer, Shiga University of Medical Science, Otsu, Japan.
Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science, the University of Tokyo, Tokyo, Japan.

Yataro Daigo (Y)

Department of Medical Oncology and Cancer Center, Shiga University of Medical Science, Otsu, Japan.
Center for Advanced Medicine against Cancer, Shiga University of Medical Science, Otsu, Japan.
Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science, the University of Tokyo, Tokyo, Japan.

Ken-Ichiro Seino (KI)

Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH